300 Northfield Road Bedford, OH 44146 MATERIAL SAFETY DATA SHEET Section I- IDENTITY Common/Trade Name: Haloperidol Lactate 5mg/mL (1mL/vial and 10mL/vial) Chemical Names: 4-[4-(p-chlorophenyl)-4-hydroxypiperidino]-4′-fluorobutyrophenone) Synonyms: Haldol®, Aldoperiden, Dozic, Einalon S, Galoperidol, Fortunan, Linton, Pernox, Serenace Manufacturer's Name: Address: Emergency Telephone Number: Chemtrec: (800) 424-9300 Telephone Number for Info.: Medical Emergency: Professional Services: (800) 521-5169 Date Prepared: Date Revised: Date Revised:
Section II - HAZARDOUS INGREDIENTS/COMPOSITION INFORMATION Other Limits Component%CAS#OSHA PELACGIH TLVRecommended Haloperidol USP
Water for Injection 98.92 7732-18-5 NONE
Haloperidol Lactate is a sterile injectable liquid drug provided in a vial. Section III - HEALTH HAZARD DATA Routes of Entry: Product may be absorbed via inhalation, ingestion, or skin contact. Health Hazard (Acute & Chronic): Haloperidol is a drug used in the treatment of psychotic disorders.
Irritation of eyes, skin, and respiratory system may result. Product affects the central nervous, cardiovascular and digestive systems. Allergic reactions may occur. Haloperidol is teratogenic and may have adverse affects on a developing fetus. Chronic exposures may cause mammary tumors or breast cancer.
Carcinogenicity: NTP? NO IARC Monographs? NONE OSHA Regulated? NO Signs & Symptoms of Exposure: Excessive exposure may cause restlessness, blurred vision, constipation,
dry mouth, muscle twitching and spasms, weakness/stiffness in arms or legs, secretion of breast milk, breathing difficulty, rapid heart rate and muscle spasms. Irritation may also occur.
Medical Conditions Generally Aggravated by Exposure: Active alcoholism, severe cardiovascular
disease, epilepsy, glaucoma, impaired liver or kidney function, hyperthyroidism, thryotoxosis, Parkinsons disease, asthma, and other respiratory illnesses.
BVL Hazard Category: 3 Section IV - FIRST AID MEASURES Eye Exposure: Flush eyes with large volumes of water for 15 or more minutes. Skin Exposure: Wash skin with cool, soapy water. Ingestion: If ingestion occurs, flush mouth with water and seek medical attention immediately. If person is
conscious, induce vomiting. Never induce vomiting on an unconscious person.
Inhalation: If difficulty breathing, administer oxygen. Seek attention of a physician immediately.
*If necessary, counteract hypotension and circulatory collapse by use of intravenous fluids, plasma, or concentrated albumin and vasopressor agents such as norepinephrine. Administer benztropine or diphenhydramine to manage severe extrapyramidal reactions. Epinephrine should not be used.
Section V - FIRE AND EXPLOSION HAZARD DATA Flash Point (Method Used): >200°F Cleveland Closed Cup LEL: not available UEL: not available Flammable Limits: Not Available Extinguishing Media: Use a multi-purpose ABC extinguisher. Special Fire Fighting Procedures: As with all fires, evacuate personnel to a safe area. Fire fighters must
wear self-contained breathing apparatus to avoid inhalation of smoke.
Unusual Fire/Explosion Hazards: None Section VI - ACCIDENTAL RELEASE INFORMATION Release to Land: Prevent entry of Haloperidol Lactate into waterways. Use absorbents to wipe up spills.
Soap and water may be used to decontaminate surfaces.
Release to Air: If aerosols are generated, reduce exposures by ventilating area and wear respiratory Release to Water: Refer to local water authority; drain disposal is not recommended. Refer to local, state
Section VII - PRECAUTIONS FOR SAFE HANDLING AND USE Steps to be taken in case material is released or spilled: See Section VI above. Wear all necessary
protective equipment including nitrile gloves, protective clothing, safety glasses and an air-purifying respirator with HEPA (P100) and organic vapor cartridges.
Waste Disposal Method: Dispose of waste according to local, state, and federal guidelines. Incineration is Precautions to be taken in handling and storing: Store product at 15-30°C or 59-86°F. Protect from light Other Precautions: None Section VIII - CONTROL MEASURES AND PERSONAL PROTECTIVE EQUIPMENT Respiratory Protection: Under normal use, respirators are not required. If aerosols are generated,
an air-purifying respirator with HEPA (P100) and organic vapor cartridges may be worn. For large spill emergencies, SCBA may be required. Personnel wearing respirators should be fit tested and approved for respirator use under the OSHA Respiratory Protection Standard 29 CFR 1910.134.
Ventilation: Use with adequate ventilation. Protective Gloves: Latex or nitrile Eye Protection: Safety glasses or goggles Other Protective Clothing or Equipment: Lab coat Work/Hygienic Practices: Wash hands following use. No eating, drinking, or smoking while handling
Section IX - PHYSICAL/CHEMICAL CHARACTERISTICS Physical State: Liquid Specific Gravity: Approximate to water Appearance and Odor: Pale yellow, clear with odor Melting Point: Liquid at room temperature Boiling Point: Approximate to water Evaporation Rate: Approximate to water Vapor Pressure: Approximate to water Solubility in Water: Soluble Vapor Density: Approximate to water pH: 3.0-3.6
Section X - STABILITY AND REACTIVITY DATA Stability: Stable Incompatibility (Materials to Avoid): Oxidizers Hazardous Decomposition or Byproducts: Decomposition products of this compound may include
potentially hazardous byproducts of nitrogen oxides, carbon monoxide, and sulfur dioxide.
Hazardous Polymerization: Will not occur Conditions to Avoid: Avoid contact with oxidizers Section XI - TOXICOLOGICAL INFORMATION Toxicity data is for the active ingredient, Haloperidol: RTECS # EU1575000
Additional reproductive health data is available from the National Institute for Occupational Safety and Health (NIOSH) Registry of Toxic Effects of Chemical Substances (RTECS). Section XII - ENVIRONMENTAL IMPACT INFORMATION Information is currently not available on the environmental impact of Haloperidol. Handle in a manner to prevent spills or releases to the environment. Section XIII - DISPOSAL INFORMATION Dispose of according to local, state, and federal guidelines. Recommend disposal via incineration
in an approved, licensed incinerator. Section XIV - TRANSPORTATION INFORMATION Haloperidol Lactate is not D.O.T. hazardous according to 49 CFR 172.101 Haloperidol Lactate not a Marine Pollutant Section XV - REGULATORY INFORMATION
SARA 313 listed?: NO CERCLA listed?: NO RCRA listed?: NO Listed on California's Proposition 65 as Code DF
Section XVI - OTHER DATA 1.
Use of this product should be through or under the direction of a physician.
This MSDS does not address the therapeutic use of this material.
Persons administering this drug to patients must be careful to avoid needle sticks to syringes and other sharps used in the administration. All needle sticks must be reported to your company management.
BVL Hazard Category Definitions (internal hazard ranking used by Ben Venue Laboratories): 1 = Low Toxicity 2= Moderate Toxicity 3 = Potent or Toxic 4 = Highly Potent or Toxic 5 = Extremely Potent or Toxic
OEL=Occupational Exposure Limit. An internal limit set by Ben Venue Laboratories for the recommended limit of employee exposure to airborne dusts or aerosols that should not be exceeded over an eight-hour time-weighted average.
Haloperidol Lactate may be considered a Hazardous Drug as described in the NIOSH Alert: Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings. Employees who prepare or administer hazardous drugs or who work in areas where these drugs are used should follow specific handling guidelines in order to prevent exposure to these agents in the air or on work surfaces, clothing, or equipment.
The Following Guidance Information is excerpted from the NIOSH Alert:
Elements of a Hazardous Drug Handling Program include:
• Establishment and implementation of written policies and protocols to ensure the safe
handling of oncolytic and/or potent drugs, including receipt of product.
• Training and education of employees on the recognition, evaluation and control of
• Effective Planning and design of the workplace • Use of best practice control measures and specialized equipment such as ventilated cabinets
or isolators designed for worker protection
• Wearing recommended personal protective equipment • An integrated health surveillance program that: includes the assessment and counseling of
prospective employees before they commence any work involving oncolytic and/or potent drugs and related waste
Published guidance on the handling and transport of cytotoxic drugs:
NIOSH Alert - Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings
National Study Commission on Cytotoxic Exposure: Recommendation for handling Cytotoxic Agents:
This document is generated to distribute health, safety and environmental data. It is not a specification sheet and none of the displayed data should be construed as a specification. Information on this MSDS sheet was obtained from sources which we believe are reliable, and we believe that the information is complete and accurate. However, the information is provided without any warranty, express or implied, regarding its correctness. Some of the information presented and conclusions drawn are from sources other than direct test data of the substance. The conditions or methods of handling, storage, use and disposal of the product are beyond our control and may also be beyond our knowledge. It is the user's responsibility to determine the suitability of any material for a specific purpose and to adopt such safety precautions as may be necessary. If the product is used as a component in another product, this MSDS information may not be applicable. For these reasons, we do not assume any responsibility and expressly disclaim liability for any loss, damage or expense arising out of or in any way connected with the handling, storage, use or disposal of this product
THE CONSTRUCTION INDUSTRY’S BENEFIT PLAN MESSAGE FROM THE BOARD OF TRUSTEES The Board of Trustees of The Construction Industry's Benefit Plan is pleased to provide you with a comprehensive benefit plan for you and your family. Your employer has recognized the importance of group insurance coverage and is committed to providing such coverage for their workforce. This plan offers the unique featu
Fachinformation (Zusammenfassung der Merkmale des Arzneimittels/SPC)Bei Diabetikern kann eine SSRI-Behandlungden Blutzucker beeinflussen. Die Dosierungvon Insulin und/oder oralen Antidiabetikamuss möglicherweise angepasst werden. Citalopram muss bei allen Patienten, bei de-Patienten mit Einschränkung der Leberfunk-nen Krampfanfälle auftreten, sofort abgesetztwerden. Citalopram darf Pati